Stock listing

OTC:CARM Carisma Therapeutics, Inc. Stock

Follow Carisma Therapeutics, Inc. into a list and get an email when it puts out news.

Carisma Therapeutics, Inc. logo
Ticker
OTC:CARM
Asset type
Stock
Exchange
OTC
Currency
USD

Carisma Therapeutics, Inc. on 6ix

Decks
1 deck · latest 2024

Valuation

balance Sep 30, 2025

Enterprise value
No market cap
P/E
No market cap
EV/sales
No market cap
EV/EBITDA
No market cap
Price/book
No market cap
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
-1.02

Forecasts

1 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
1.00 USD · Analysts' mean
EPS, year to Dec 2025
-0.69 · 1 analyst

Team and board

Officers

OfficerRole
Steven KellyPresident, Chief Executive Officer and Director
Richard MorrisChief Financial Officer

Board

DirectorRole
Marella ThorellDirector
Steven KellyPresident, Chief Executive Officer and Director

Events

QuarterResults
Q3 2025Nov 12, 2025
Q2 2025Aug 7, 2025 · After close
Q1 2025May 13, 2025 · After close
Q4 2024Mar 31, 2025 · Before open
Q3 2024Nov 7, 2024 · Before open
Q2 2024Aug 8, 2024 · Before open
Q1 2024Apr 1, 2024 · Before open
Q4 2023Mar 6, 2024 · After close
Q3 2023Nov 9, 2023 · Before open
Q2 2023Aug 10, 2023 · Before open
All 20 quarters
QuarterResults
Q1 2023May 11, 2023 · Before open
Q4 2022Feb 28, 2023 · Before open
Q3 2022Nov 7, 2022 · Before open
Q2 2022Aug 8, 2022 · Before open
Q1 2022May 9, 2022 · Before open
Q4 2021Feb 28, 2022 · Before open
Q3 2021Nov 8, 2021 · Before open
Q2 2021Aug 9, 2021 · Before open
Q1 2021May 10, 2021 · Before open
Q4 2020Mar 15, 2021 · Before open

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (2024)Investor deck69 slides2024

Open Decks

Financials

Annual, in USD

Income statement

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Revenue19.6M14.9M9.83M26.5M11.2M425.0K30.0M990.0K
Cost of revenue59.7M74.1M6.09M85.0K219.0K208.0K
Gross profit-40.0M-59.2M9.83M26.5M11.2M-219.0K-208.0K425.0K30.0M990.0K
Research and development59.7M74.1M56.6M25.2M23.3M24.4M13.9M12.2M12.2M26.0M
Selling, general and administrative20.1M29.5M9.38M6.41M5.09M12.2M11.6M8.07M14.7M9.85M
Operating income-62.2M-88.7M-56.2M-28.2M-28.4M-36.9M-25.7M-20.0M6.17M-35.2M
Depreciation and amortization3.35M2.84M6.09M682.0K448.0K219.0K208.0K285.0K178.0K366.0K
EBITDA-58.8M-85.9M-50.1M-27.5M-27.9M-36.7M-25.5M-19.7M6.34M-34.8M
Interest expense1.94M3.15M8.26M1.47M247.0K1.40M
Income before tax-60.5M-86.9M-61.2M-8.61M-28.3M-107.5M-33.7M-29.0M1.90M-33.5M
Income tax-60.5M8.10M-3.88M-8.27M-29.0K46.9K5.00K1.40M
Net income-60.5M-86.9M-61.2M-336.0K-28.3M-107.5M-33.7M-29.0M1.89M-33.5M
Earnings per share, basic-1.46-2.59-1.52-0.04-4.80-23.65-10.91-22.241.74-35.23

Balance sheet

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash and equivalents17.9M77.6M24.2M162.6M55.4M48.1M50.4M14.7M25.3M36.1M
Short-term investments925.0K027.8M
Receivables2.86M825.0K24.5M
Inventory-825.0K-24.5M
Current assets23.8M80.5M54.6M205.6M62.9M54.4M51.8M15.0M25.9M36.3M
Property, plant and equipment13.4M5.66M5.19M
Goodwill13.1M13.1M13.1M13.1M13.1M16.9M
Total assets30.5M89.6M72.2M312.6M188.5M114.4M111.6M75.1M104.1M36.8M
Accounts payable2.08M3.93M1.73M2.85M3.10M1.90M1.37M907.0K1.67M1.25M
Current liabilities16.1M15.9M19.7M11.6M18.0M8.52M6.11M4.72M3.98M7.58M
Long-term debt33.7M
Total debt2.48M3.12M40.2M2.63M3.44M13.9M
Total liabilities58.4M63.0M214.8M140.9M197.7M141.1M67.4M57.1M65.4M17.9M
Shareholders' equity-27.9M26.5M-157.1M171.7M-9.23M-26.7M44.2M18.0M38.7M18.9M
Shares outstanding41.5M33.5M40.3M9.12M5.91M4.55M3.09M1.30M1.09M949.6K

Cash flow

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations-59.9M-81.2M-7.57M-37.3M-27.0M-37.5M-22.8M-17.8M2.62M-34.5M
Capital spending-123.0K-1.13M-4.66M-1.87M-440.0K-136.0K-2.00K00-287.0K
Free cash flow-60.0M-82.3M-12.2M-39.2M-27.5M-37.7M-22.8M-17.8M2.62M-34.8M
Cash from investing-123.0K72.4M-32.6M-1.87M-440.0K-136.0K-2.00K98.0K461.0K-287.0K
Cash from financing344.0K62.2M35.8M16.0M72.3M35.4M58.6M7.00M-13.8M16.8M
Dividends paid-147.0K
Change in cash-59.7M53.4M-138.4M-23.2M44.8M-2.30M35.7M-10.7M-10.7M-18.0M

Open Financials

Cap table

Built by 6ix from Carisma Therapeutics, Inc.’s releases

Common shares
41,845,078
Fully diluted
41,845,078

Fully diluted

LineShares
Common shares41,845,078

Share count over time

CountShares
Nov 22, 202641,845,078

Open Cap table

Shareholders

HolderSharesOf the companyAs of
Union Bancaire Privee, UBP SA785<0.01%Sep 30, 2026
Ascentis Independent Advisors200<0.01%Sep 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Briggs Morrison
Other companies: CRISPR Therapeutics AG (Director · Since at least Jun 5, 2025); Werewolf Therapeutics, Inc. (Director · Since at least Apr 29, 2021); Arvinas, Inc. (Chair of the Arvinas Board of Directors · Since at least Sep 26, 2018); Codiak BioSciences Inc (Director · Oct 13, 2020 – Feb 17, 2021 · Past); Oncorus Inc (Director · Oct 1, 2020 – Oct 1, 2020 · Past); Repare Therapeutics Inc (Director · Jun 18, 2020 – Jun 17, 2024 · Past); NextCure, Inc. (Director · May 8, 2019 – Jun 11, 2020 · Past); Syndax Pharmaceuticals, Inc. (Director · Mar 2, 2016 – Feb 7, 2024 · Past)
Director · Mar 7, 2023 – Jun 26, 2024 · Past
John Hohneker
Other companies: ArriVent BioPharma, Inc. (Director · Since at least May 16, 2024); Curis, Inc. (Director · Since at least Dec 2, 2021); Humanigen Inc (Director · Oct 19, 2021 – Jul 27, 2022 · Past); Aravive Inc (Director · May 12, 2021 – Sep 23, 2022 · Past); Evelo Biosciences, Inc. (Director · Jan 27, 2021 – Jun 8, 2023 · Past); Dimension Therapeutics (Director · Jan 18, 2017 – Nov 7, 2017 · Past)
Director · Apr 1, 2024 – Jun 26, 2024 · Past
Marella Thorell
Other companies: Seres Therapeutics, Inc. (EVP, Chief Financial Officer · Since at least Mar 25, 2024); ESSA Pharma Inc (Director · Since at least Oct 1, 2020); Evelo Biosciences, Inc. (Chief Financial Officer · Jul 13, 2022 – Nov 7, 2023 · Past); Centessa Pharmaceuticals PLC (Chief Accounting Officer · May 27, 2021 – Mar 21, 2022 · Past); GRI Bio, Inc. (Director · Feb 9, 2021 – Dec 13, 2022 · Past)
Director · Since at least Jun 30, 2024
Michael Torok
Other companies: Amarin Corporation plc (Non-Executive Director · Since at least Apr 3, 2025)
Director · Mar 7, 2023 – Jun 26, 2024 · Past
Sohanya Cheng
Other companies: Karyopharm Therapeutics Inc. (EVP & Chief Commercial Officer · Since at least Jun 7, 2021)
Director · Oct 31, 2024 – Oct 31, 2024 · Past
Steven Kelly
Other companies: Artelo Biosciences, Inc. (Director · Since at least Jun 21, 2019)
President and CEO, Director · Mar 7, 2023 – Jan 28, 2025 · Past
Bjorn OdlanderDirector · Mar 7, 2023 – Mar 7, 2023 · Past

Open People

Log in to ask 6ix AI your own questions about Carisma Therapeutics, Inc.